



EUROPEAN
COMMISSION

Brussels, **XXX**
SANTE/10642/2021 ANNEX
(POOL/E1/2021/10642/10642-EN
ANNEX.docx)
[...](2021) **XXX** draft

ANNEX

ANNEX

to the

COMMISSION REGULATION (EU) .../...

**refusing to authorise certain health claims made on foods, other than those referring to
the reduction of disease risk and to children's development and health**

ANNEX

Rejected health claims

| Application – Relevant provisions of Regulation (EC) No 1924/2006 | Nutrient, substance, food or food category | Claim | EFSA opinion reference |
|---|--|---|-------------------------------|
| Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data | <i>Bifidobacterium animalis</i> subsp. <i>lactis</i> Bi-07 (Bi-07) | <i>Bifidobacterium animalis</i> subsp. <i>lactis</i> Bi-07 contributes to the improvement of lactose digestion in individuals who have difficulty digesting lactose | Q-2020-00024 |
| Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data | Coffee C21, a blend of pure Arabica roast coffees (<i>Coffea arabica</i> L.) without any non-coffee ingredients | Regular consumption of Coffee C21 contributes to the maintenance of DNA integrity in cells of the body | Q-2019-00423 |
| Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data | MenaQ7 [®] , vitamin K2 as menaquinone-7 | MenaQ7 [®] , vitamin K2 as menaquinone-7, improves arterial stiffness | Q-2019-00229 |